EGRP News Flash - May 26, 2009
Freedman Named Chief of EGRP's Clinical and Translational Epidemiology Branch
The National Cancer Institute's (NCI) Epidemiology and Genetics Research Program (EGRP) is pleased to announce the appointment of Andrew N. Freedman, Ph.D., as Chief of its Clinical and Translational Epidemiology Branch (CTEB). The branch supports, directs, and stimulates research on clinical, environmental, and genomic factors that influence cancer progression, recurrence, new primary cancers, and mortality. It also supports and coordinates research on factors that contribute to the development of cancer among individuals with underlying diseases and conditions. His appointment is effective May 25.
Dr. Freedman joined NCI's Division of Cancer Control and Population Sciences (DCCPS) in 1997 as a molecular epidemiologist in the Applied Research Program's (ARP) Risk Factor Monitoring and Methods Branch. He developed and supported a program of research in cancer risk prediction, genetic susceptibility testing, pharmacoepidemiology and pharmacogenomics, and managed research contracts, interagency and cooperative agreements, and a grant portfolio pertaining to these research areas. Dr. Freedman also directed multidisciplinary molecular, clinical, and translational epidemiology studies within the Health Maintenance Organization (HMO) Cancer Research Network (CRN); Department of Veterans Affairs medical system; NCI's Surveillance, Epidemiology, and End Results (SEER) Program; and the NIH-AARP Diet and Health Study. He is internationally recognized for his work in molecular cancer epidemiology and cancer risk prediction.
In the areas of pharmacoepidemiology and pharmacogenomics, Dr. Freedman has developed research collaborations with several NIH Institutes and Centers and other agencies within the U.S. Department of Health and Human Services (HHS). He is Chair of the Trans-NCI Pharmacoepidemiology and Pharmacogenomics Working Group, and represents NCI on the Trans-NIH Pharmacogenomics Working Group and the Institute of Medicine (IOM) Roundtable on Translating Genomic-Based Research for Health.
His research interests include developing, applying, and evaluating prediction models for cancer risk and prognosis, developing benefit/risk indices for pharmaceuticals used to prevent and treat cancer, and identifying clinical, epidemiologic, and pharmacogenomic factors related to cancer treatment outcomes.
Before joining DCCPS, Dr. Freedman was a Postdoctoral Research Fellow in the Genetic Epidemiology Branch of NCI's Division of Cancer Epidemiology and Genetics (DCEG). He earned his Ph.D. in Epidemiology from the University of Buffalo and Roswell Park Cancer Institute. He also received an M.S. in Social and Preventive Medicine from the University of Buffalo and a B.S. in Biology from the University of Binghamton.